A novel series of aryl piperazine substituted heterocycles has been synthes
ized and identified as antagonists of the alpha (1a) adrenergic receptor (a
lpha (1a)-AR), which has been implicated in benign prostatic hyperplasia (B
PH). These compounds selectively inhibit binding to the alpha (1a)-AR with
K(i)s as low as 2.1 nM. (C) 2000 Elsevier Science Ltd. All rights reserved.